Long-term complications and screening
Last reviewed November 17, 2026. OwieClear editorial team. Waiting for clinician review. Not medical advice. Talk with your doctor about your own care.
The complications of type 1 diabetes are the same as those of type 2, and they are driven by the same thing: years of glucose above the normal range.
What is different is the length of exposure. Someone diagnosed at eight has sixty years of glucose management ahead, which is why early control matters so much.
Related pages: Type 1 diabetes
The bottom line
- Complications come from damage to small and large blood vessels.
- Intensive glucose control substantially reduces eye, kidney and nerve complications.
- Early good control carries benefit for decades afterwards, called metabolic memory.
- Screening detects eye and kidney damage before symptoms.
- Cardiovascular disease is the leading cause of death in type 1 diabetes.
- The optimal glucose targets across different ages.
- Why some people with poor control avoid complications.
- Whether time in range predicts complications as well as A1C.
The story, step by step
What the evidence labels mean
What DCCT showed
What happens
The trial that settled the question.
What the research shows
- The Diabetes Control and Complications Trial, reported in 1993, compared intensive with conventional glucose control in type 1 diabetes.
- Intensive control dramatically reduced eye, kidney and nerve complications, by a large margin.
- It also increased severe hypoglycemia, which is the trade-off that still shapes how targets are set today.
- Long-term follow-up of the same participants found that the benefit persisted for decades after the groups' control converged, an effect called metabolic memory or legacy.
- That follow-up also showed reduced cardiovascular events in the group that had been treated intensively early.
- The practical conclusion is that control in the first years of diabetes buys protection that cannot be recovered later.
Why it matters
Metabolic memory is the strongest argument for pushing hard early, and the strongest argument against treating a difficult first few years as unimportant.
What's still uncertain
- How long the legacy effect persists.
- Whether time in range produces the same legacy.
Read more
- NIDDK: The A1C test and diabetesGovernment
- American Diabetes Association: standards of care resourcesNonprofit
- NIDDK: Type 1 diabetesGovernment
Next: Eyes
Retinopathy and screening
What happens
Preventable blindness.
What the research shows
- High glucose damages the small vessels of the retina, which leak, close off, and provoke fragile new vessels that bleed.
- There are no symptoms until damage is advanced, which is the entire reason for screening.
- Screening in type 1 usually starts within three to five years of diagnosis, and at puberty in children diagnosed young, then at intervals set by the findings.
- Treatment with laser, injections into the eye and surgery works far better when started early.
- Blurred vision in the weeks after a large improvement in control is usually temporary lens swelling, not retinopathy. Rapid improvement can also transiently worsen existing retinopathy, which is why eyes are checked before major changes.
- Retinopathy can progress quickly in pregnancy, so screening is repeated during it.
Why it matters
Almost all diabetes-related blindness is preventable, and the preventive step is an appointment rather than a treatment.
What's still uncertain
- The best screening intervals for people with no retinopathy.
- How much artificial-intelligence screening will improve access.
Read more
- National Eye Institute: Diabetic retinopathyGovernment
- MedlinePlus: Diabetes complicationsGovernment
- American Diabetes Association: standards of care resourcesNonprofit
Next: Kidneys and nerves
The quieter damage
What happens
Urine tests and foot checks.
What the research shows
- Kidney damage begins silently. The urine albumin-to-creatinine ratio detects it years before blood tests change, and should be checked annually, usually starting five years after diagnosis.
- Blood pressure control, with an ACE inhibitor or ARB where albumin is leaking, slows progression substantially.
- Nerve damage usually starts in the toes and feet: numbness, tingling, burning or pain, often worse at night.
- The numbness is what causes harm, because injuries go unnoticed and become ulcers.
- Annual foot examination including sensation testing, plus daily self-inspection, prevents most serious foot problems.
- Autonomic nerve damage can affect digestion, bladder, blood pressure on standing and sexual function, and it blunts the warning signs of low blood sugar.
Why it matters
The link between autonomic neuropathy and hypoglycemia unawareness is worth knowing, because it connects two problems that are usually discussed separately.
What's still uncertain
- How to improve rates of urine albumin testing.
- Which treatments genuinely help painful neuropathy.
Read more
- NIDDK: Diabetic kidney diseaseGovernment
- NIDDK: Diabetes and foot problemsGovernment
- MedlinePlus: Diabetes complicationsGovernment
Next: Heart and vessels
The leading cause of death
What happens
Often under-treated in type 1.
What the research shows
- Cardiovascular disease is the leading cause of death in type 1 diabetes, and risk is raised compared with people without diabetes.
- Risk rises with duration of diabetes, with kidney involvement, and with the usual factors: blood pressure, lipids, smoking and family history.
- Blood pressure and cholesterol are checked regularly, and statin treatment is considered from around age 40, earlier with additional risk factors.
- Cardiovascular risk in type 1 is frequently under-treated compared with type 2, partly because people are younger and appear low risk on standard calculators.
- Standard risk calculators were not developed for type 1 and underestimate risk in this group.
- Stopping smoking is the single largest modifiable intervention available.
Why it matters
A 35-year-old with 25 years of type 1 diabetes is not the low-risk patient a standard calculator suggests, and treating them as one is a common error.
What's still uncertain
- The best cardiovascular risk tools for type 1.
- When to start statins in type 1.
Read more
- MedlinePlus: Diabetes complicationsGovernment
- American Diabetes Association: standards of care resourcesNonprofit
- NIDDK: Type 1 diabetesGovernment
Next: The schedule
What should happen each year
What happens
A list worth holding the clinic to.
What the research shows
- A1C every three to six months, interpreted alongside time in range from sensor data.
- Blood pressure at every visit, and a lipid panel periodically.
- Urine albumin-to-creatinine ratio and kidney function annually, usually from five years after diagnosis.
- A dilated eye examination on the schedule set by the eye specialist.
- A foot examination at least annually, with sensation testing.
- Thyroid function periodically, and coeliac screening where symptoms or growth suggest it, because both are more common in type 1.
- A review of injection or infusion sites, insulin doses, hypoglycemia episodes and glucagon availability, plus vaccinations and a conversation about mood.
Why it matters
Asking for the urine albumin test and the foot examination by name is worthwhile, because both are high-value and both are commonly skipped.
What's still uncertain
- How to improve completion rates of annual reviews.
- The best screening intervals for associated autoimmunity.